Anti-nociceptive effect of dexmedetomidine in a rat model of monoarthritis via suppression of the TLR4/NF-κB p65 pathway.

Dong Ji,Yalan Zhou,Shuangshuang Li,Dai Li,Hui Chen,Yuanchang Xiong,Yuqiu Zhang,Hua Xu
DOI: https://doi.org/10.3892/etm.2017.5196
IF: 2.7
2017-01-01
Experimental and Therapeutic Medicine
Abstract:As a therapeutic target for neuropathic pain, the anti-nociceptive effects of alpha 2-adrenoceptors (alpha 2AR) have attracted attention. Dexmedetomidine (DEX), a potent and highly selective alpha 2AR agonist, has exhibited significant analgesic effects in neuropathic pain, but the underlying mechanism has remained elusive. The present study investigated the effect of DEX on Toll-like receptor (TLR) 4 and nuclear factor (NF)-kappa B p65 expression, as well as the production of pro-inflammatory cytokines. The rat monoarthritis (MA) model was induced by intra-articular injection of complete Freund's adjuvant (CFA) at the ankle joint. After induction of MA, the rats were intrathecally treated with normal saline or DEX (2.5 mu g) for 3 consecutive days. The concentration of interleukin-1 beta and -6 as well as tumor necrosis factor-alpha was examined by ELISA. The expression levels of TLR4 and NF-kappa B p65 were determined by western blot analysis and immunohistochemistry. The results indicated that the pro-inflammatory cytokines TLR4 and NF-kappa B p65 were significantly upregulated in MA rats. DEX treatment markedly reduced mechanical and thermal hyperalgesia, suppressed MA-induced elevation of the pro-inflammatory cytokines and inhibited the TLR4/NF-kappa B p65 pathway, while these effects were blocked by pre-treatment with the selective alpha 2AR antagonist BRL44408 (15 mu g) at 30 min prior to CFA injection. These results suggested that DEX has an antinoci-ceptive effect via suppressing the TLR4/NF-kappa B p65 pathway.
What problem does this paper attempt to address?